The Novartis Board of Directors announced today, that it is nominating Ms. Elizabeth Doherty and Mr. Ton Buechner for election to the Board at the Annual General Meeting (AGM) of Shareholders to be held on February 23, 2016.
Ms. Doherty is a finance professional with a career spanning more than 35 years in the fast moving consumer goods industry where she developed strategies and programs to improve business outcomes and drive shareholder value. Ms. Doherty is a British national and seasoned professional having served as a CFO and member of the Board of Directors on numerous corporations.
Mr. Buechner is the CEO and Chairman of the Executive Board of AkzoNobel, a Dutch multinational active in the fields of decorative paints, performance coatings and specialty chemicals. As a business leader and engineer by training, Mr. Buechner has successfully led global companies with portfolios targeting both business to business and direct to consumer activities.
Source: Novartis
The U.S. Patent and Trademark Office issued a patent to MedTrace for their method of diagnosing the human heart via 15O-water PET. The patented method is the foundation of the company’s software aQuant, currently under development. Hendrik “Hans” Harms, PhD and Senior Scientist at MedTrace, and Jens Soerensen, Professor and Clinical Advisor to MedTrace, are the originators of the method.
Teresa Graham, currently head of global product strategy for Roche pharma, will become the division’s new CEO next month, Roche said Thursday. Simultaneously, Roche is elevating Levi Garraway, chief medical officer, to the executive committee.
Fierce Pharma has obtained internal documents and video of a town hall meeting conducted this week describing what J&J called a “comprehensive review” of its portfolio. Moving forward, J&J plans to operate its vaccines and infectious diseases outfits as one group, the executives explained.